Choose a language and wait for the translated text.
Shots:
Merck (MSD) & Isomorphic Labs have entered into a research collaboration that combines Isomorphic Labs’ AI approach to drug discovery with Merck’s proprietary data resources & discovery experience
Isomorphic Labs will perform in silico predictions & deliver molecular designs for small molecule candidates against an oncology target using its drug design engine (IsoDDE), incl. select proprietary datasets supplied by Merck, while Merck will be responsible for preclinical & clinical development, manufacturing & commercialization
Isomorphic Labs will receive an upfront payment & is eligible for research, development, regulatory & commercial milestones, plus tiered royalties on net sales; it also receives an option to co-fund development in return for elevated royalties (financial terms not disclosed)
Ref: Merck | Image: Merck | Isomorphic Labs | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Merck and Isomorphic Labs Enter into a Strategic Research Collaboration to Discover Small Molecules Against an Oncology Target appeared first on PharmaShots.